SBI Life Insurance reduced its stake in Granules India Limited from 3.30% to 2.84%, selling 1,140,433 shares for ₹95.14 Cr at ₹833.80 apiece.
A pharmaceutical manufacturer engaged in producing Active Pharma Ingredients, Pharmaceutical Formulation Intermediates, and finished dosages for global markets. Granules India operates integrated manufacturing facilities across multiple locations in India, serving domestic and international customers in the pharmaceutical sector. The company specializes in complex chemical synthesis and formulation development for various therapeutic categories, including antibiotics, cardiovascular, and gastroenterology segments.
Joint venture between State Bank of India and BNP Paribas Cardif. Manages over Rs 4.7 lakh crore in total AUM with the flagship SBI Life Equity Fund alone holding over Rs 77,000 crore. One of India's largest private life insurers by AUM, with a multi-cap equity book deployed across ULIP and participating funds.
